Pilot study describing the use of pravastatin in pediatric renal transplant recipients

Pediatric Transplantation

Volumn 7, Issue 3, 2003, Pages 179-184

  Butani, Lavjay ^a   Pai, Monica V ^a   Makker, Sudesh P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hypercholesterolemia; Pediatric; Pravastatin; Renal; Transplantation

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; PREDNISONE; TACROLIMUS;

ADOLESCENT; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MYALGIA; PEDIATRIC SURGERY; PILOT STUDY; RECIPIENT; RETROSPECTIVE STUDY; SIDE EFFECT; STUDENT T TEST; SURVIVAL RATE; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; CASE-CONTROL STUDIES; CHILD; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; PILOT PROJECTS; PRAVASTATIN; RETROSPECTIVE STUDIES;

EID: 0038317612     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2003.00036.x     Document Type: Article

References (27)

1. SHARMA AK, MYERS TA, HUNNINGHAKE DB, MATAS AJ, KASHTAN CE. Hyperlipidemia in long-term survivors of pediatric renal transplantation. Pediatr Transplant 1994: 8: 252-257.
2. PENNISI AJ, FIEDLER J, LIPSEY A, MICKEY R, MALEKZADEH MH, FINE RN. Hyperlipidemia in pediatric renal allograft recipients. J Pediatr 1975: 87: 249-251.
3. SINGH A, TEJANI C, BENFIELD M, TEJANI A. Sequential analysis of the lipid profile of children post-renal transplantation. Pediatr Transplant 1998: 2: 216-223.
4. PIRSCH JD, D'ALESSANDRO AM, SOLLINGER HW, et al. Hyperlipidemia and transplantation: etiologic factors and therapy. J Am Soc Nephrol 1992: 2: S238-S242.
5. THE WRITING GROUP FOR THE DISC COLLABORATIVE RESEARCH GROUP. Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated LDL lipoprotein cholesterol. JAMA 1995: 273: 1429-1435.
6. DISLER PB, GOLDBERG RB, KUHN L, MEYERS AM, JOFFE BI, SEFTEL HC. The role of diet in the pathogenesis and control of hyperlipidemia after renal transplantation. Clin Nephrol 1981: 16: 29-34.
7. SHEN SY, LUKENS CW, ALONGI SV, SFEIR RE, DAGHER FJ, SADLER JH. Patient profile and effect of dietary therapy on post-transplant therapy. Kidney Int 1983: 24: S147-S152.
8. DELUCCHI A, MARIN V, TRABUCCO G, et al. Dyslipidemia and dietary modification in Chilean renal pediatric transplantation. Transplant Proc 2001: 33: 2008-2013.
9. GOLDBERG RB, ROTH D. A preliminary report of the safety and efficacy of Fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. Am J Cardiol 1995: 76: 107A-109A.
10. YOSHIMURA N, OKA T, OKAMOTO M, OHMORI Y. The effects of Pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992: 53: 94-99.
11. HOLDAAS H, HARTMANN A, STENSTROM J, DAHL KJ, BORGE M, PFISTER P. Effect of Fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995: 76: 102A-106A.
12. KATZNELSON S, WILKINSON AH, KOBASHIGAWA JA, et al. The effect of Pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation 1996: 61: 1469-1474.
13. MASSY ZA, GUIJARRO C. Statins: effects beyond cholesterol lowering. Nephrol Dial Transplant 2001: 16: 1738-1741.
14. PALINSKI W, TSIMIKAS S. Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol 2002: 13: 1673-1681.
15. PENSON MG, FRICKER FJ, THOMPSON JR, et al. Safety and efficacy of Pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant 2001: 20: 611-618.
16. SCHWARTZ GJ, BRION LP, SPITZER A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987: 34: 571-590.
17. KASISKE BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1998: 84: 985-992.
18. PIRSCH JD, Voss BJ, ROECKER EB, et al. Predictive factors for immunologic graft failure in cadaver renal transplant recipients. Transplant Proc 1991: 23: 1282-1283.
19. DEMOGRAPHY OF DIALYSIS AND TRANSPLANTATION IN CHILDREN IN EUROPE, 1985. Report from the European Dialysis and Transplant Association Registry. Nephrol Dial Transplant 1998: 3: 235-243.
20. MASSY ZA, GUIJARRO C, WIEDERKEHR MR, MA JZ, KASISKE BL. Chronic renal allograft rejection: immunologic and non-immunologic risk factors. Kidney Int 1996: 49: 518-524.
21. MARKELL MS, SUMRANI N, DIBENEDETTO A, FRIEDMAN EA. Effect of early hyperlipidemia on graft and patient survival in cyclosporine-treated renal transplant patients. Am J Kidney Dis 1993: 22: 233-239.
22. KNIPSCHEER HC, BOELEN CCA, KASTELEIN JJP, et al. Shortterm efficacy and safety of Pravastatin in 72 children with Familial Hypercholesterolemia. Pediatr Res 1996: 39: 867-871.
23. SANJAD SA, AL-ABBAD A, AL-SHORAFA S. Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. J Pediatr 1997: 130: 470-474.
24. COLEMAN JE, WATSON AR. Hyperlipidemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. Pediatr Nephrol 1996: 10: 171-174.
25. CHRISTIANS U, JACOBSEN W, FLOREN LC. Metabolism and drug interactions of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Transplant Patients: are the statins mechanistically similar. Pharmacol Ther 1998: 80: 1-34.
26. SINZINGER H, SCHMID P, PIRICH C, et al. Treatment of hypercholesterolemia in children. Lancet 1992: 340: 548-549.
27. STEIN EA, ILLINGWIRTH DR, KWITEROVICH PO, et al. Efficacy and safety of Lovastatin in adolescent males with heterozygous familial hypercholesterolemia. JAMA 1999: 281: 137-144.